This week, shares in AstraZeneca fell more than 4 percent after the disappointing outcomes of a data abstract on its experimental precision drug, datopotamab deruxtecan, used in lung cancer patients in a late-stage trial. The abstract was published ahead of the European Society for Medical Oncology’s (ESMO) congress, which will begin in Madrid on October…

Read more →